ATP2A2
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
As of the edition of 20 October 2026, ATP2A2 (sarcoplasmic/endoplasmic reticulum calcium ATPase 2, UniProt P16615) has 2 drugs tested at it and 6 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P16615
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 15
- Disease areas
- Cancer; Heart and blood vessels; Urinary and reproductive; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Istaroxime | Active | Phase 3 | none listed |
| Mipsagargin | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| GenSpera | Route A |
The other 5 companies at ATP2A2
In the product6 companies in all; 5 are not named here, and no score is.
See the 6 companies at ATP2A2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.